Galectin-3 and Oncofetal-Fibronectin Expression in Thyroid Neoplasia as Assessed by Reverse Transcription-Polymerase Chain Reaction and Immunochemistry in Cytologic and Pathologic Specimens
- 1 August 2003
- journal article
- research article
- Published by Mary Ann Liebert Inc in Thyroid®
- Vol. 13 (8) , 765-770
- https://doi.org/10.1089/105072503768499662
Abstract
Oncofetal fibronectin (onfFN) and galectin-3 (Gale-3) have been proposed as possible tools for the preoperative diagnosis of thyroid carcinomas, based on the finding that the expression of both onfFN and Gale-3 are significantly increased in papillary and anaplastic carcinomas, compared to normal thyroid tissues and follicular adenomas. In this study we analyzed the expression of these markers by immunochemical and molecular analysis of benign and malignant thyroid tumors. Sixty-five thyroid nodules, consisting of 20 follicular adenomas (FAs) and 45 papillary thyroid carcinomas (PTCs) at final histology were examined. At the molecular level, among the 45 PTCs, 44 (97.8%) showed a variable level of onfFN mRNA, while 8 of the 20 (40%) adenomas expressed the same marker. Similar results have been found analyzing Gale-3 expression: 97.8% of PTC and 55% of FAs were positive for this marker. Immunohistochemistry (IHC) for Gale-3 was positive in 42 of 45 (93.3%) PTC tissues. Staining was invariably confined to the cytoplasm, with a homogeneous distribution in the large majority of the neoplastic cells. The 3 negative cases (6.7%) were represented by 2 classic variants of PTC and 1 follicular variant of PTC. Eighteen of the 20 (90.0%) adenomas stained negative for Gale-3. A significant association was found between positive staining and malignant phenotype (p < 0.0001). Gale-3 protein expression was also performed on samples obtained by ex vivo fine-needle aspiration (FNA) in 35 PTCs by immunocytochemistry (ICC). Immunoreactivity was present in 32 (91.0%) and negative in 3 (8.8%) cases. With the exception of 1 case (negative by ICC and positive by IHC), ICC and IHC were fully concordant. In conclusion, our results indicate that a search for Gale-3 protein overexpression by IIC or ICC, but not by reverse transcription-polymerase chain reaction (RT-PCR), may yield an additional marker of malignant potential of thyroid nodular lesions, and may be a useful adjunct to the currently available diagnostic tools for the preoperative diagnosis of malignant thyroid tumors.Keywords
This publication has 32 references indexed in Scilit:
- Expression of galectin‐3 in fine‐needle aspirates as a diagnostic marker differentiating benign from malignant thyroid neoplasmsCancer, 1999
- Measurement of the Expression of Oncofetal Fibronectin mRNA in Thyroid Carcinomas by Competitive Reverse Transcription-Polymerase Chain ReactionThyroid®, 1999
- Expression of c‐erbB‐2 oncoprotein in human thyroid tumoursHistopathology, 1999
- Dipeptidyl aminopeptidase IV in the cytologic diagnosis of thyroid carcinomaDiagnostic Cytopathology, 1998
- Fine-Needle Aspiration of Thyroid: An Institutional ExperienceThyroid®, 1998
- Expression of the endogenous galactose‐binding protein galectin‐3 correlates with the malignant potential of tumors in the central nervous systemCancer, 1997
- GALECTIN‐3 AND LAMININ EXPRESSION IN NEOPLASTIC AND NON‐NEOPLASTIC THYROID TISSUEThe Journal of Pathology, 1997
- Increased Expression of CD44 Variants in Differentiated Thyroid CancersJapanese Journal of Cancer Research, 1996
- EGF‐receptors in human normal and pathological thyroid tissueHistopathology, 1996
- Diagnostic pitfalls in thyroid fine‐needle aspiration: A review of 394 casesDiagnostic Cytopathology, 1993